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Abstract: Malaria causes approximately 2 million deaths each year primarily in
children. The clinical manifestations of the disease are the result of invasion and lysis of
red blood cells by Plasmodium parasites, the deadliest of which is Plasmodium
falciparum. In order to accomplish this cycle of invasion, Plasmodium falciparum
utilizes a number of proteins including EBA-175 of the Ebl family of proteins. In this
thesis, I examine the interactions between EBA-175 and its receptor GpA and selfassociation of EBA-175 towards understanding the role of this interaction in invasion. I
develop protocols for expression and purification of RII-175, F2-175, GpA, and FITCRII-175, as well as, protocols for pulldowns of RII-175 by GpA that identify the minimal
binding domain of GpA. I also develop and optimize a FACS assay to quantify RII-175
binding to GpA on RBCs and utilize the assay to asses the ability of 3’-siallylactose and a
peptide backbone to inhibit binding. I further examine the influence of 3’-siallylactose
and a peptide backbone on RII-175 self-association. Lastly, I describe the development
of monoclonal antibodies against RII-175 that will be used in future studies to further
characterize interactions between RII-175 and GpA. These studies define the minimal
binding domain of GpA that interacts with RII-175 is the region corresponding to amino
acids 30 to 50. It was also shown that 3’-siallylactose, which is important for receptor
binding, is a weak inhibitor of binding while a peptide backbone corresponding to the
minimal binding domain cannot inhibit binding alone. Thus, a fully glycosylated region
of amino acids 30-50 is required. The self-association studies of the Kd of dimerization
of RII-175 is ~10uM consistent with dimerization being important for receptor binding.
In agreement with the inhibition studies, 3’-siallylactose and peptide backbone failed to
i

influence dimerization. Further understanding of the RII-175/GpA interactions will help
to define their roles in invasion and can lead to the production of better malaria
therapeutics.
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Chapter 1: Introduction
Malaria kills approximately 2 million individuals a year and causes illness in
approximately 200 million annually [1]. The clinical manifestations of malaria are the
result of the invasion and lysis of red blood cells (RBCs) by Plasmodium parasites [1].
Of the four species of Plasmodium that cause malaria, Plasmodium falciparum is the
deadliest [1]. P. falciparum can be found world wide in tropical regions [fig 1]. The
region most affected by P. falciparum is sub-Saharan Africa [2].
Plasmodium parasites represent a heavy economic burden for countries where
malaria is endemic [2]. As such, research has been conducted with the goal of creating
vaccines and or drug treatments against Plasmodium parasites. This has become more
important as strains of parasites become increasingly drug resistant. A large variety of
proteins and cellular processes have been identified as potential targets for vaccines and
drugs. One such target is Erythrocyte Binding Antigen (EBA-175), which is involved in
the erythrocyte stage of the parasite life cycle and is the focus of this thesis.
1.1: Malaria Life Cycle
The Plasmodium parasite has a complicated life cycle that involves two different
hosts and multiple stages within each host [1-3]. The two hosts for the parasite are
humans and the anopheles mosquito. Within the mosquito, the cycle consists of uptake
of gametocytes during a blood meal followed by the formation of a macrogametocyte [3].
The gametocyte develops into an ookinete and then a cyst. The cyst then ruptures
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releasing sporozoites that travel to the salivary glands of the mosquito and are ultimately
injected into the human host during the next blood meal [3].
Once within the human host the parasite undergoes two main stages in its life
cycle. These stages are the liver stage followed by the erythrocyte stage [3]. The liver
stage consists of invasion, replication within, and lysis of multiple types of liver cells.
The liver stage culminates in the production of merozoites that can go on to infect RBCs
[1, 3]. The parasite invades, replicates within, and lyses RBCs in the erythrocyte stage.
It is the continual invasion and lysis of RBCs which causes the clinical symptoms of
malaria that include fatigue and severe anemia, which can lead to death [1, 3]. This stage
is targeted by many antimalarials including the chloroquines. Also included in the
erythrocyte stage is the formation of gametocytes during replication within RBCs.
1.2: Invasion of Red Blood Cells by Parasite
Invasion of RBCs in of itself is also a complicated process involving two main
pathways of invasion and multiple proteins in each pathway. The overall invasion
process can be broken down into four main steps [fig 3] [1]. The first step involves low
affinity interactions between the merozoite and RBC. Merozoite Surface Protein-1
(MSP-1) and Apical Membrane Antigen-1 (AMA-1) are both membrane proteins
expressed on the surface of merozoites during the erythrocytic stage and are involved in
this stage of invasion. Although MSP-1 is the most abundant surface protein, the receptor
for MSP-1 and how it mediates attachment have yet to be defined. AMA-1 has two roles
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in invasion. The first is attachment through an unknown receptor to the RBC surface and
initiation of the second stage [1].
The second stage involves the apical reorientation of the merozoite so that the
apical end contacts the RBC membrane and high affinity interactions and the formation
of the tight junction [1]. The apical reorientation is initiated by AMA-1 through an
unknown mechanism. The proteins responsible for the formation of the tight junction are
the Erythrocyte Binding Ligand (EBL) and Reticulocyte-binding Homology (RH)
families of proteins are involved in this stage of invasion and are essential for invasion.
Both the EBL and RH families of proteins are expressed during the erythrocytic stage.
The EBA-175, EBA-140 (BAEBL), and EBA-181 (JESEBL) of the EBL family
represent the sialic acid dependent pathway and are important for binding erythrocytes
[fig 4]. The RH family of proteins represents both the sialic acid dependent and the sialic
acid independent pathway of invasion and are important for binding both erythrocytes
and reticulocytes [1].
The third step of invasion is the movement of the tight junction over the surface
of the merozoite and the shedding of the protein coat [1]. The parasite utilizes an
actin/myosin motor complex to achieve the active invasion of the RBC. The forth step of
invasion is the complete invasion of the RBC and the formation of the parasitophorous
vacuole [1].
1.3: EBL Family of Proteins
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The EBL family of proteins is involved in the sialic acid dependent pathway of
RBC invasion. The EBL family includes EBA-175, EBA-140 (BAEBL), EBA-181
(JESEBL), and EBL-1 of P. falciparum and Duffy Binding Protein (DBP) of P. vivax [fig
4] [1, 4, 5]. The receptors for EBA-175, EBA-140, and EBL-1 are GpA, GpC, and GpB
respectively, while the receptor for EBA-181 is still unknown. The receptor for DBP is
the Duffy Antigen Receptor for Chemokines [1, 4, 5]. The sialic acid dependence of
EBA-175, EBA-140, and EBA-181 was discovered by treating RBCs with neuraminidase
from V. cholerea, which cleaves the α2-3 linked sialic acid from o-linked glycans [4, 610]. Treatment of the RBCs caused the loss of binding by EBA-175, EBA-140, and
EBA-181 in rosetting assays [4, 6-10]. In these assays, the malarial protein is expressed
on the surface of adherent mammalian cells in tissue culture and RBCs are flowed over
the adherent cells. The RBCs form rosettes, large clumps of RBCs, over the top of the
cells expressing the malaria protein. A positive result in a rosetting assay is the formation
of the rosettes overtop of the adherent mammalian cells.
The EBL family proteins share homology in their receptor binding domains. The
receptor binding domains contain one to two Duffy Binding like (DBL) domains and are
homologous to Duffy binding region of DBP [1, 5]. The DBL domains are primarily
alpha-helical and include multiple conserved cysteines [5]. DBP contains one DBL
domain and the others family members contain two DBL domains [fig 4]. The two DBL
domains of EBA-175 comprise a larger receptor binding domain named Region II (RII)
spanning amino acids 145 to 761. The two DBL domains within RII-175 F1 and F2 span
amino acids 153 to 427 and 442 to 748 respectively [5].
4

1.4: EBA-175
EBA-175 was originally discovered by taking merozoite stage parasite
supernatant and incubating the supernatant with RBCs [11]. These experiments showed
multiple proteins which bound RBCs including one with a molecular weight of 175kDa.
This protein was named EBA-175 [11]. It was later determined that EBA-175 was part
of the EBL family proteins and expressed by many strains of P. falciparum. Many lab
and wild strains such as 3D7 and W2mef use EBA-175 as the primary invasion protein
[9].
The receptor for EBA-175 was discovered through rosetting assays [fig 5] [6]. In
these assays, RBCs were treated with trypsin and chymotrypsin and RII-175 expressing
cells were only able to bind chymotrypsin treated cells. GpA and GpB are the main
chymotrypsin resistant, trypsin sensitive proteins on the surface of RBCs. To distinguish
between these two receptors, GpA and GpB negative RBCs were then used in rosetting
assays and RII-175 was able to bind GpB negative cells but not GpA negative cells [6].
These experiments established GpA as the receptor for RII-175.
EBA-175 has also been suggested as a target for malarial vaccines. EBA175’s potential as a target for vaccine development has been supported by the evidence
that antibodies against EBA-175 can be found in patient sera of individuals infected with
P. falciparum [12, 13]. Individuals who have high titers of antibodies against EBA-175
also have marginal protection against infection by P. falciparum [12, 13].
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The structure of RII of EBA-175 was recently solved [fig 6] [5]. In the crystal
structure, RII-175 appears as a dimer. In the dimer, the F1 of one monomer interacts
with the F2 of the monomer in a handshake configuration. The dimer creates two
channels going through the center of the dimer, and the surface of these channels is
highly basic. The F2 domain of each monomer make up roughly two-thirds of two
channels with the other third contributed by the F1 domains. Mutations in the dimer
interface showed a loss of RBC binding in rosetting assays and this result supports the
biological relevance of the dimer model. Cocrystallization with 3’-siallylactose also
showed six glycan binding sites in the dimer with 4 sites inside the channels and the other
2 on the receptor facing surface. The glycan binding sites were found by cocrystallizing
3’-saillylactose with RII-175 [5].
1.5: GpA
GpA is the major siallylated protein on the surface of RBCs and with another
transmembrane protein, Band3, make up over 50% of the proteins on the surface of RBCs
[15-16]. GpA is a single pass transmembrane protein that can exist as both a homodimer
and a heterodimer with GpB on the surface of RBCs. GpA has three extracellular exons
with a total of 15 O-linked glycans and 1 N-linked glycan on approximately 60 amino
acids. The glycans make up approximately 50% of the total molecular weight of 33kDa.
The O-linked glycans are important for receptor binding by RII-175 [15-16].
GpA is part of a family of proteins that includes GpB and GpE and shares
approximately 95% sequence homology with its family members [fig 5] [15-16]. It is
6

thought that GpB and GpE were derived from homologous recombination as is the case
for the 43+ known variants of GpA that are derived primarily from GpB but also less
commonly with GpE. The majority of the variants are located in exon 3 of GpA.
Homologous recombination can occur because GpB and GpE both contain an exon 3 in
the nucleotide sequence. GpA is the only family member that expresses an exon 3 due to
a splice site mutation in exon 3 of both GpB and GpE. Exon 3 contains four O-linked
glycans that are unique to GpA [15-16]. It is plausible that RII-175 may directly contact
exon 3 of GpA due to the uniqueness of this sequence.
The rosetting assays and the crystal structure with glycan binding sites suggest
two possible models of receptor binding by RII-175 [fig 6] [5]. RII-175’s receptor is
GpA, which exists on the surface of RBCs as both a homodimer and a heterodimer with
GpB. One models suggest are that the GpA dimer threads through the channels to form
the complex with the glycans in the right orientation. The other model suggests that the
GpA dimer wraps around the outside of the RII-175 dimer and places the glycans in the
right orientation [5].
1.6: Focus and scope of thesis
While it is known that GpA is the receptor for EBA-175, little is known about
how they interact. It is not known how EBA-175 differentiates between GpA and GpB,
which differ by only 32 amino acids. It has yet to be shown if these 32 amino acids are
important for the specific binding of GpA by EBA-175. While a dimer model of EBA175 binding to GpA has been proposed, the exact stoichiometry of binding has yet to be
7

defined. The crystal structure of the EBA-175/GpA complex has also not yet been
solved.
My thesis focuses on the identifying the minimal binding domain of GpA for
EBA-175 along with the characterization of binding and the characterization of EBA-175
dimerization. In chapter 2, I describe the development and optimization of expression
systems and purification of RII-175 and GpA and the mapping of the minimal binding
domain of GpA. In chapter 3, I describe the development and optimization of a
functional assay for RII-175 that forms the basis for addressing the receptor specificity of
RII-175 and inhibition of receptor binding by components of the receptor described in
chapter 4. In chapter 5, I characterize the dimerization of RII-175 using biophysical
methods. In chapter 6, I describe the development of monoclonal antibodies against RII175.
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Figure 1: W.H.O. 2006 incidence map of P. falciparum[2]
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Figure 2: Life cycle diagram for Plasmodium parasites [3]
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a)

b)
Figure 3: a) Diagram of a merozoite and its organelles, b) Scheme for invasion of RBCs
by merozoite [1]
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Figure 4: a) Domain structure of EBL family proteins, b) Alignment of EBA-175, EBA140, EBA-181, and EBL-1 amino acid sequence [5]
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a)

b)
Figure 5: a) Exons and glycosylations for GpA, GpB, GpE [15], b) Identification of
GpA as the receptor for RII-175 [6]
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d)
e)

Figure 6: a) ribbon structure of RII-175 monomer, b) alingment of F1, green, and F2,
purple, c) structure of RII-175 monomer, d) structure of RII-175 dimer with glycan
binding sites, e) RII-175 dimer and glycan binding site mutants [5]
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Figure 7: Dimer model of GpA binding [5]
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Chapter 2: Expression of RII-175 and GpA and Mapping of the Minimal Binding
Domain of GpA
2.1: Introduction
Protein Expression and purification allows for the study of protein/protein
interactions outside of the context of cells or organisms and reduces the potential
masking properties of other proteins present in cells. RII-175 was previously expressed
in Pichia pastoris and purified by various chromatography methods [5]. The
recombinant RII-175 was a glycosylation mutant where certain residues were mutated to
remove potential aberrant glycosylation by P. pastoris. The mutations were important for
expression because P. falciparum lacks complex glycosylation of proteins [5]. Because
expression using the Pichia pastoris system is labor and time intensive especially for the
study of multiple mutations, an E. coli system was developed. The E. coli system also
has the advantage of not requiring the use of glycosylation mutants due to the E. coli
lacking a glycosylation system and can be readily used to generate multiple mutants
when needed.
GpA has also been expressed before using multiple lines of CHO cells [14]. The
cell lines used were wild type for glycosylation as well as deficient in various stages of
O-linked and N-linked glycosylation. GpA with different types and amounts of
glycosylation was produced by using these cell lines. Unfortunately, these GpA
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constructs were expressed on the surface of the CHO cells and large quantities could not
be produced using this system [14].
Recently a group has developed a protocol for expression of proteins in a
mammalian expression system [17]. This system utilizes HEK293T cells and the
pHLFchis or pHLSec vectors. These vectors use a β-chicken actin promoter to drive the
expression of large amounts of the protein cloned into the various vectors. Both the
pHLFchis and pHLSec vector function have signal sequences for the export of the
expressed protein outside of the cells. The protein can then be purified from the media
[17]. Due to the ability of these vectors to produce large quantities of soluble protein, I
optimized this system for GpA in order to express soluble protein, which is an advantage
over the CHO cell expression system. This system was also chosen because it allows for
the complete glycosylation of GpA, which can not be done in bacterial expression
systems.
While the receptor has been identified for RII-175 through rosetting assays, the
portion of the receptor directly bound by RII-175 has yet to be identified. Previously,
fragments of GpA were tested for their ability to inhibit RBC binding in rosetting assays
[6]. These fragments were obtained by enzymatically cleaving GpA obtained from RBCs
to produce multiple fragments. No individual fragment was able to inhibit RII-175
binding to RBCs to the same extent as full length GpA [6]. As a result of the enzymatic
cleavage of Gpa from RBCs, only a limited number of fragments could be obtained and
tested. This method limits the regions that can be used and can cause a binding domain
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to be missed due to cleavage within the domain. This may be why none of the fragments
produced were able to inhibit RII-175 binding to RBCs. The cleavage sites for trypsin on
GpA are found in exon 3, which results in fragments with incomplete exon 3’s [6]. This
may be important to understanding why the fragments did not inhibit because exon 3 is
the only portion of sequence unique to GpA.
In this chapter, I describe protocols that were developed for the production of RII175 and GpA. These protocols form the basis for the production of recombinant protein
for all subsequent studies. In this chapter, I also describe the optimization of a protocol
for pulldowns with full length and the truncations of GpA and the binding of GpA
truncations by RII-175 to show functionality of the expressed proteins and to identify the
minimal binding domain.
2.2: Materials & Methods
2.2.1: Expression of EBA-175. RII-175 (amino acids 145 to 761) and F2-175 (amino
acids 442 to 748) were expressed in BL-21 E. coli cells using a pet28 vector. The cells
were grown shaking at 37oC to an O.D. 600 of 0.6 and induced with IPTG. The cells
were then grown for an additional 3 to 5 hours shaking at 37oC. The cells were then
pelleted and resuspended in 10mL/L cells of 50mM Tris pH 8, 100mM NaCl, 5mM DTT,
0.25mg/mL Lysozyme, and 1 complete protease tablet per 30mL of buffer and frozen at 80oC. The cells were later lysed using sonication and the inclusion bodies pelleted. The
inclusion bodies were washed 3 times in 50mM Tris pH 8, 100mM NaCl, 5mM DTT,
0.5% Triton X-100 and once in 50mM Tris pH 8, 100mM NaCl, 5mM DTT. The protein
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was then denatured with 6M guanidine hydrochloride, 50mM Tris pH 8, 100mM NaCl,
5mM DTT overnight at 4oC. 100mg of protein was used per liter of refolding buffer
(200mM Tris pH 8, 10mM EDTA, 400mM L-arginine, 0.1mM PMSF, 2mM reduced
glutathione, 0.2mM oxidized glutathione). The protein was refolded for 48 to 72 hours at
4oC. The refolded protein was concentrated using Amicon concentrators to a
concentration of approximately 15mL per liter of refolding buffer. The concentrated
protein was dialyzed overnight at 4oC against 50mM MES pH 6, 200mM NaCl (1L
dialysis buffer per 1L refolding buffer). The dialyzed protein was then concentrated to
5mL/1L refolding buffer. Each 5mL of protein was then purified by gel filtration
chromatography using a Hiload 16/60 superdex 200 prepgrade column with 10mM MES
pH 6, 200mM NaCl and the peak fractions of each run were combined and purified by
gel filtration chromatography an additional 2 to 3 times. The peak fractions from the
final gel filtration purification were than concentrated to a concentration of 15mg/mL.
2.2.2: Expression of GpA. GpA_FL (aa1-60) and GpA truncations [table 1], cloned
into a pHLFchis vector containing the GpA signal sequence, were transiently transfected
into 70-90% confluent HEK293T cells using the method described in Aricescu 2006.
Media was then harvested four days later. The media was diluted 3 times with His-tag
buffer A (50mM Tris pH 8, 100mM NaCl, 10mM Imidazole pH 8). The diluted media
was then run over a nickel-agarose column and eluted with His-tag buffer B (50mM Tris
pH 8, 100mM NaCl, 500mM Imidazole pH 8). To separate out the various glycosylation
states of the GpA produced, the GpA was purified by anion exchange chromatography
using a monoQ 5/50 GL column with buffers (A) 25mM Tris pH 8 and (B) 25mM Tris
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pH 8, 1M NaCl. A gradient from 0 to 40% of buffer B was used to separate the various
glycosylation states which eluted at 130mM NaCl and 230mM NaCl.
2.2.3: GpA Binding in a Pulldown. 40ug of each GpA construct (full length and
truncations) was incubated with 1uL 15mg/mL RII-175 and 20uL of ProteinA beads in a
total of 100uL in 50mM Tris pH 8, 200mM NaCl, 0.1% Triton X-100 for 30min on ice.
The beads were then washed 3 times. The beads were then resuspended in 10uL of SDSPAGE dye and the samples run on a 10% SDS-PAGE gel.
2.3: Results
2.3.1: RII-175 Expression and Purification
An E. coli system was chosen for the expression of RII-175 and F2-175 because it
can produce milligram quantities of protein quickly and without the use of glycoslylation
mutants. F2-175 was expressed and purified in addition to RII-175 because it has similar
binding ability to the full regionII. Both his-tagged and untagged RII-175 and F2-175
were expressed in E. coli using the pet28 vector. The denatured protein extracted from
the E. coli inclusion bodies was refolded in standard refolding buffer as described in
Materials and Methods. Multiple methods were tried to purify the refolded protein. The
first method of purification was to concentrate 1L of refolded protein which was then
purified by gel filtration chromatography with Tris buffer pH 8 and 200mM NaCl. The
subsequent peak was purified by cation exchange chromatograpy. Unfortunately, this
method resulted in aggregate protein precipitating on the gel filtration column. As a
result, other methods of purification were developed.
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The next method used was to concentrate the refolded protein and dialyze the
protein against 50mM MES pH 6 200mM NaCl. Dialysis at this step prevented
precipitation of the protein on the columns. The dialyzed protein was then purified by
anion exchange chromatography. The resultant peak was further purified by gel filtration
chromatography. Unfortunately, this protein still had aggregate in the purified sample.
The next method of purification was to use the previous method and add two to
three additional gel filtration chromatography steps to reduce aggregate contamination.
This resulted in protein with minimal aggregate contamination. While this method
resulted in pure protein it was time and labor intensive.
The method was modified in an attempt to reduce the time and labor needed to
produce the recombinant protein. The method used was to follow the previous method
but exclude the cation exchange step because the cation exchange step did not increase
the purity of the protein. This method resulted in similar purification to the previous
method with one less step.
The final protocol used was to refold the protein in standard refolding buffer and
dialyze the refolded protein. The dialyzed protein was then purified by three to four
rounds of gel filtration chromatography. A typical GF200 chromatograph and SDSPAGE gel of the fractions corresponding to the major peak can be found in figure 8. A
typical yield for this protocol is 1-5mg per liter of refolding buffer.
2.3.2: GpA Expression and Purification
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A mammalian expression system was chosen for GpA because it could be used to
produce milligram quantities of completely glycosylated protein quickly. The
extracellular portion of GpA (amino acids 1 to 60) was cloned into the pHLFchis
construct with the addition of a precision protease site between the GpA sequence and the
Fc sequence [fig 9]. The GpA construct was transiently transfected into HEK293 cells.
A time course was done to measure the production of GpA over time [fig 9]. The
expression of GpA peaked at four days post transfection. All subsequent transfections
were harvested four days post transfection.
GpA was purified from the media using a nickel-agarose column. The resulting
eluted protein was then used in subsequent experiments. The GpA at this point appears
as a smear on an SDS-PAGE gel that is likely the result of various stages of glycosylation
in the GpA sample. The different glycosylation states can be further separated by anion
exchange chromatography presumably because of the difference in charge represented by
the negatively charged sialic acid containing glycans [fig 9].
2.3.3: Expression and Purification of GpA Truncations:
Previously only full length GpA has been expressed and only as a transmembrane
protein on the surface of CHO cells. Also, the fragments of GpA used in experiments to
inhibit binding were produced through enzyme treatment of GpA from RBCs. This
expression system was developed to produce multiple overlapping fragments of GpA and
mutants quickly.
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Overlapping truncations of the extracellular portion of GpA were cloned into the
pHLFchis vector [table 1]. The truncations were transiently transfected into HEK293
cells and the media harvested four days post transfection. All truncations expressed
under these conditions [fig 10]. While truncations 3, 5, and 2-4 expressed well,
truncation 2 only expressed moderately well and truncations 1 and 4 expressed poorly.
Never-the-less, all truncations of GpA can be obtained.
2.3.4: Optimization of Pulldown Conditions
A method to examine protein/protein interactions in the absence of cells has not
been developed for Gpa and RII-175, therefore, I developed a pulldown assay to examine
the binding of GpA by RII-175 in a cell free assay. The first pulldowns used nickelagarose beads in conjunction with the his-tag on the GpA [fig 11]. In this pulldown, GpA
was purified by cation exchange chromatography, which resulted in three distinct peaks
and each peak was incubated with RII-175. Peak 2 and Peak 3 of GpA bound RII-175 in
the pulldown. Unfortunately, the RII-175 bound non-specifically to the nickel-agarose
beads.
In order to eliminate the non-specific binding of RII-175 to the nickel-agarose
beads, the imidazole in the wash buffer was increased from 10mM to 100mM. Peak 2
and Peak 3 of GpA still bound RII-175 in the pulldown. Unfortunately, the RII-175 still
bound non-specifically to the nickel-agarose beads.
In order to eliminate any non-specific binding by RII-175, the type of beads used
was changed to proteinA-agarose beads [fig 11]. ProteinA-agarose beads can be used
23

with the GpA constructs because all GpA contructs are conjugated to the Fc portion of an
IgG antibody and proteinA binds the Fc portion of antibodies. The three peaks of GpA
were again used and peak 2 bound RII-175. All three peaks showed binding, but the
higher molecular weight peaks bound RII-175 the most. Unfortunately, while there was
less non-specific binding of RII-175 on the proteinA beads, the non-specific binding was
not completely eliminated.
In order to eliminate all non-specific binding by RII-175, a detergent was added to
the wash buffer [fig 11]. The three peaks of GpA were again used and peak 2 bound RII175. Only the higher molecular weight peaks bound RII-175. In this pulldown, there
was no non-specific binding of the beads by RII-175. The final conditions used in the
pulldown were 50mM Tris pH 8, 50mM NaCl, 0.1% Triton X-100 and proteinA-agarose
beads.
2.3.5: Pulldown with GpA Truncations
In order to identify the portion of Gpa bound by RII-175, a pulldown was
conducted with full length and truncations of GpA. The first pulldown conducted was
with the buffer used in the above experiment. At 50mM NaCl, all the truncations bound
RII-175.
To eliminate any non-specific binding of RII-175 by a salt gradient was used [fig
12]. The salts used were 50mM NaCl, 100mM NaCl, and 200mM NaCl. All truncations
bound RII-175 at 50mM NaCl and 100mM NaCl. At 200mM NaCl, full length GpA and
truncation 4 bound RII-175 strongly. Truncation 2 also weakly bound RII-175.
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2.4: Discussion
A protocol to purify RII-175 and F2-175 from E. coli was developed and
optimized. The final yield for this protocol is approximately 1 to 5 mg/ L refolding
buffer. A protocol for the production of full length GpA and GpA truncations using
HEK293 cells was developed and optimized. The final yield for this protocol is
approximately 13mg/L harvested media. The production of purified RII-175 and GpA
allows for further investigation into the interactions between RII-175 with itself and its
receptor.
To show that RII-175 and GpA (full length and truncations) are functional a
pulldown protocol was developed. In the pulldown, RII-175 binds truncation 4 the
strongest of all the truncations. Truncation 4 corresponds to amino acids 30 to 50 of GpA
and includes all four glycosylations in exon 3. It is likely that amino acids 30 to 50 of
GpA are the minimal binding site for RII-175. RII-175 also binds truncation 2 weakly.
Truncation 2 contains seven glycosylations and an additional three residues that could
potentially be glycosylated. RII-175 may bind truncation 2 weakly because of the large
number of glycosylations. The glycosylations are important for binding as evidenced by
the loss of binding in rosetting assays upon treatment with neuraminidase. This is also
seen in the pulldown with the anion exchange purified GpA. In this pulldown, RII-175
binds only the high molecular weight peaks which may correspond to a higher level of
glycosylation. Development of further functional assays for RII-175 are described in the
next chapter.
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a)

b)

Figure 8: a) GF200 column purification of RII-175, b) GF200 column purification of F2-175
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a)

b)

d)

c)
Figure 9: Expression of GpA a) diagram of GpA construct, b) Nickel column
purification of HEK293T cells transfected with either no vector, pHLFchis vector, or
GpA vector (full length), c) Time course of GpA production by transfected HEK293T
cells, d) anion exchange purification of GpA
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Truncation:

Sequence:

1

SSTTGVAMHTSTSSSVTKSY

2

TSTSSSVTKSYISSQTNDTHK

3

YISSQTNDTHKRDTYAATPRA

4

KRDTYAATPRAHEVSEISVRT

5

AHEVSEISVRTVYPPEEETGE

2-4

TSTSSSVTKSYISSQTNDTHKRDTYAATPRAHEVSEISVRT

Table 1: Amino acid sequence of the extracellular portion of GpA in each truncation
clone and diagram of truncations with glycosylations (red) O-linked, (blue) N-linked
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Figure 10: Expression of GpA full length and truncations purified by Nickel-agarose
column
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a)

b)

c)

Figure 11: RII-175 Pull down with GpA purified on MonoQ column a) 10mM Imidazole
washes on nickel beads, b) proteinA beads, c) proteinA beads with 0.1% trition X-100 washes
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Figure 12: GpA pulldown of RII with full length GpA and GpA truncations
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Chapter 3: Validation of Protein Binding in a Functional Assay
3.1: Introduction
Flow Cytometry (FACS) is a method often used to differentiate populations
within samples of cells [18]. In FACS, a sample is injected into a flow cell and then
flows past a laser at approximately 1 cell at a time. The cell scatters light in both the
forward and side directions and is read by a set of detectors [fig 13]. The forward scatter
gives the approximate size of the cell that passed by the laser. The side scatter detects
organelles like the granules found in neutrophils. Both types of scatter can be used to
define different populations in a sample like peripheral blood [18].
FACS can also be used to detect fluorescent stains and dyes by adding additional
lasers and detectors. [fig 13] [18]. Fluorescent dyes that bind DNA can be used to detect
P. falciparum infected RBCs from uninfected RBCs due to only the parasite having
DNA. The uninfected RBCs can be separated from infected RBCs based on the detection
of fluoresce if the flow cytometer is attached to a cell sorter. Fluorescent dyes conjugated
to antibodies can also be used in FACS to detect proteins on the surface of cells or
proteins in complex with proteins on the surface of cells [18]. Multiple dyes can be used
at once to differentiate between different populations. Both the forward and side scatter
and the fluorescence detection can be combined to easily differentiate population of cells
in mixed samples [18].
In this chapter, I describe the development of a functional FACS assay for the
recombinant RII-175 purified as described in chapter 2. FACS assays can be used to test
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a multitude of conditions for binding and can be used to obtain the IC50s for inhibitors
and protein/protein interactions on the surface of cells.
3.2: Materials and Methods
3.2.1: Initial Binding of RBCs by RII-175. Red blood cells (RBC) were obtained from
the Barnes Jewish Children’s Hospital Blood Bank. 500,000 RBCs are diluted in 500uL
DMEM with 10% FCS. His tagged 15mg/mL RII-175 was added to a concentration of
either 66uM or 9uM and the mixture incubated on ice for one hour. The RBCs were then
washed three times with DMEM with 10% FCS. Mouse anti-his antibody from Qiagen
was added to the RBCs. Alexafluor 647 conjugated anti-mouse IgG antibody from
Invitrogen was diluted 1:500 in DMEM with 10% FCS. 100uL of the diluted antibody
was added to the washed RBC and incubated on ice for one hour. The RBCs were then
washed three times. The RBCs were then resuspended in 100uL DMEM with 10% FCS.
The RBCs were then analyzed using a fluorescent microscope.
3.2.2: Optimization of Enzyme Treatment of RBCs to Prevent Clumping. RBCs
were incubated with 1mg/mL chymotrypsin overnight. The cells were then used as
described above in RII binding.
3.2.3: Optimization of Anticoagulant treatments to Prevent Clumping. EDTA: RII175 was incubated with RBCs as described in above in RII binding with the buffer being
DMEM 10% FCS 7mM EDTA instead of DMEM 10% FCS. Heparin: RII-175 at 10uM
and 1uM was incubated with RBCs in DMEM 10% FCS buffer with heparin at

33

concentrations of 60units/mL, 30units/mL, or 12 units/mL. The mixture was then
incubated with antibodies as described above in RII binding.
3.2.4: Optimization of Salt and Protein Concentration conditions to Prevent
Clumping. RII-175-his at 0nM, 40nM, 200nM, 320nM, and 1000nM were each
incubated with RBCs in DMEM 10% FCS with 150mM NaCl, 200mM NaCl, 250mM
NaCl, 300mM NaCl, 350mM NaCl, and 400mM NaCl for 1 hour on ice. The samples
were then washed three times with DMEM 10% FCS that have their corresponding salt
concentration. The samples were then incubated with anti-his antibody conjugated to
FITC for 1 hour on ice. The samples were then washed three times with DMEM 10%
FCS that have their corresponding salt concentration. The RBCs were resuspended in
2mL DMEM 10% FCS that have their corresponding salt concentration and were then
analyzed using a BD FACScanto machine available in the Goldberg lab.
3.2.5: FITC labeling of RII-175 and FACS. 1.5mg of 15mg/mL RII-175 was diluted in
1mL PBS pH 6, 50mM EDTA and mixed with 10uL 10mg/mL FITC in DMSO. The
mixture was incubated rotating at room temperature for 1hr. The mixture was then
diluted in 10mL 25mM MES pH 6, 100mM NaCl. The diluted protein was then run over
2mL monoS sepharose resin and the protein eluted with 5mL 25mM MES pH 6, 500mM
NaCl. The protein was then concentrated to 1mL and purified by gel filtration
chromatography using a superdex 200 10/300 GL column. Incorporation of the FITC
label was verified using a phosphoimager. The resultant labeled peak was then
concentrated to 15mg/mL. 1uM RII-FITC was then added to 500,000 RBCs in 500uL of
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DMEM 10% FCS 250mM NaCl and incubated for one hour on ice. The cells were
washed three times with DMEM 10% FCS 250mM NaCl and resuspended in 2mL
DMEM 10% FCS 250mM NaCl. The cells were then imaged using a fluorescent
microscope and also analyzed using a BD FACScanto machine available in the Goldberg
lab.
3.3: Results
3.3.1: Initial Binding of RBCs by RII-175
To initially asses the ability of the recombinant RII-175 to bind RBCs, 66uM RII175-his purified as described in chapter 2 was added to RBCs and then incubated with a
mouse anti-his antibody followed by a goat anti-mouse IgG antibody conjugated to Alexa
647. The RBCs were then imaged using a fluorescent microscope [fig 14]. Only the
RBCs incubated with RII-175 were positive for fluorescence. The RBCs incubated with
RII-175 also formed large clumps that do not resuspend and were positive for
fluorescence while negative controls lacking RII-175 did not fluoresce or clump. This
was also seen when the RII-175 concentration was decreased to 9uM. The clumping only
occurs when RBCs are incubated with RII-175 and is therefore RII-175 dependent.
F2-175 has a similar binding ability as RII-175 when used in rosetting assays and
was therefore tested for binding RBCs in solution. F2-175-his was also incubated with
RBCs at the same concentrations as previously used for RII-175. The F2-175 also
clumped the RBCs and these clumps were positive for fluorescence [fig 15]. The F2-175
also clumping indicates that it is a property of the recombinant protein binding to RBCs.
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Unfortunately, clumps are not conducive to FACS assays for two main reasons: 1) small
clumps that flow through the flow stream will be read as one event instead of multiple
events and can under represent the true percentage of the population that is positive for
binding, 2) the capillary through which the cells pass is very small and large clumps will
clog the system.
3.3.2: Optimization of Enzyme Treatment of RBCs to Prevent Clumping
The only known function for GpA is to prevent clumping of RBCs. To test if the
clumping is due to other proteins interacting when GpA is bound by RII-175, enzyme
treatment of RBCs was conducted before incubation with RII-175. Specifically
chymotrypsin was used because GpA is chymotrypsin resistant and treatment of RBCs
with chymotrypsin will cleave other proteins while leaving GpA whole. When these
treated RBCs were incubated with the lowest concentration of RII-175 previously used,
the RBCs still clumped and the clumps were positive for fluorescence. While this
treatment did not inhibit binding, the treatment did not reduce the clumping.
3.3.3: Optimization of Anticoagulant treatments to Prevent Clumping
Anticoagulants are compounds used in solutions containing RBCs to prevent
clumping and clotting of RBCs, therefore, I wanted to examine if anticoagulants could
prevent the clumping when RII-175 binds RBCs. Two commonly used anticoagulants
are EDTA and heparin. RBCs were incubated with the lowest concentration of RII-175
previously used in DMEM with EDTA at concentration of 7mM. The RBCs still
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clumped and the clumps were positive for fluorescence. Unfortunately, EDTA did not
decrease clumping significantly on its own.
Heparin was also used in an attempt to prevent clumping. RII-175 at 10uM and
1uM was incubated with RBCs and heparin at concentrations of 60units/mL, 30units/mL,
or 12 units/mL. RBCs incubated with RII-175 alone clumped cells and were positive for
fluorescence [fig 16]. Unfortunately, all concentrations of heparin prevented clumping of
RBCs but also prevented RII-175 binding in the 1uM RII-175 samples and greatly
reduced binding in the 10uM samples shown by the loss of fluorescence.
3.3.4: Optimization of Salt and Protein Concentration conditions to Prevent
Clumping
It is possible that salt and the concentration of protein could affect the clumping
of the RBCs. The next treatment used to prevent clumping of the RBCs upon RII-175
binding was a salt gradient combined with a titration of RII-175. RII-175-his at 0nM,
40nM, 200nM, 320nM, and 1000nM were each incubated with RBCs in DMEM with
150mM NaCl, 200mM NaCl, 250mM NaCl, 300mM NaCl, 350mM NaCl, and 400mM
NaCl [fig 17]. The concentration of RII-175 with the best overall binding was 1000nM
(1uM). The other concentrations did not have high enough signal to justify using. The
1uM sample bound RBCs up to 250mM NaCl, and the clumping decreased as the salt
concentration increased [fig 17]. The conditions of 1uM RII-175 and 250mM NaCl were
used in all subsequent FACS assays. Thus, it appears that the clumping is due to
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electrostatic interactions and these interactions can be limited by increasing the salt
concentration in the buffer.
3.3.5: RII-FITC labeling and use in FACS
To make the FACS assay more efficient and reduce the number of washes, RII175 was labeled with FITC. RII-175 was incubated with either FITC dissolved in DMSO
or Carbonate buffer. The lowest concentration of FITC used, 10uL of 10mg/mL DMSO,
was able to label the RII-175 [fig 17]. The RII-FITC was run over a cation exchange
resin column to purify the RII-FITC from free FITC. The subsequent protein was
purified by gel filtration chromatography. The labeled protein ran as one peak and the
FITC label was verified by a phosphoimager [fig 18]. The protein was then concentrated
to 15mg/mL and used to label RBCs. The FITC labeled RII-175 was able to bind RBCs
and was positive for fluorescence [fig 19]. The FITC labeled RII-175 when incubated
with RBCs was also able to produce a positive signal in a FACS assay [fig 19].
3.4: Discussion
Recombinant RII-175 that was expressed and purified is functional for RBCs
binding, and can now be used to characterize its interactions with GpA and itself. The
functional assay developed can be further used to study inhibitors of various kinds, i.e.
small molecules, receptor fragments, antibodies, etc. The development of the FITC-RII175 decreases the amount of time required for the FACS assay and can be used to test
inhibitors. One disadvantage to the FITC-RII-175 in a FACS assay is that the label could
interfere with the ability of antibodies specific to RII-175 to bind by obscuring the
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epitope for the antibody. Receptor specificity of the RII-175 will be described in chapter
4 and utilizes the FACS assay developed in this chapter.
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a)

b)
Figure 13: a) diagram of forward and side scatter in FACS, b) diagram of laser, filters,
and detectors in FACS [18]
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Figure 14: RII-175 binding of RBCs using a secondary antibody conjugated to
Alexafluor 647
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Figure 15: RII-175 and F2-175 binding of RBCs using a secondary antibody conjugated
to Alexafluor 647
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a)

b)

Figure 16: Influence of heparin on RII-175 binding to RBCs, a) percentage of positive cells
for heparin samples, b) Dot plots of heparin samples in “a”
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a)
b)

Figure 17: a) Salt gradient and RII-175 titration in FACS, b) Dot Plots for 1000nM
RII-175
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a)

b)

Figure 18: RII-175-FITC, a) FITC titration in Carbonate buffer and DMSO (top) FITC
fluorescence detected by phosphoimager (bottom) Commassie Brilliant Blue stain of
same gel, b) Gel filtration purification of RII-175-FITC after cation resin purification(on
gel) (top) FITC fluorescence detected by phosphoimager (bottom) Commassie Brilliant
Blue stain of same gel

45

a)

Bright Field

FITC

no RII-FITC

RII-FITC

b)

Figure 19: RII-175-FITC binding of RBCs a) RII-175-FITC fluorescence microscopy, b)
RII-175-FITC FACS
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Chapter 4: Receptor Specificity of RII-175 and Inhibition of Binding by Receptor
Components
4.1: Introduction
It has previously been shown that RII-175 binds to GpA on the surface of RBCs.
GpA is the main chymotrypsin resistant, trypsin sensitive receptor on the surface of
RBCs [6]. Trypsin cleaves GpA at two sites, amino acids 31 and 39, both of which are
located in exon 3. Rossetting assays have shown that when RBCs are incubated with
either chymotrypsin or trypsin, RII-175 can only bind the chymotrypsin treated cells [6].
This establishes a reproducible pattern for receptor specificity in binding assays.
Binding Assays have also been used to assess the potency of inhibitors. It has
previously been shown that SL can inhibit RII-175 binding RBCs in rosetting assays in
the low milimolar range [19]. Related compounds have also been analyzed in rosetting
assays. Of those tested, SL was the best inhibitor [19]. The major drawbacks to using the
rosetting assay are that you cannot readily quantify expression of the malaria protein
expressed in tissue culture and its surface expression and it is very hard to accurately
quantify the number of RBCs bound to the cells expressing the malaria protein. Along
with the inability to quantify the RBCs forming rosettes, it is also difficult to quantify
what signifies a rosette (i.e. 5 RBCs or 100 RBCs). Other binding assays like a FACS
assay can be used to accurately and quantitatively assess the potency of inhibitors.
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In this chapter, I describe the receptor specificity of RII-175 and the use of small
molecules in an inhibition study using the quantitative FACS assay developed in chapter
3.
4.2: Materials and Methods
4.2.1: RII-175 binding to RBCs. Red blood cells (RBC) were obtained from the Barnes
Jewish Children’s Hospital Blood Bank. 500,000 RBCs were diluted in 500uL DMEM
with 10% FCS. His tagged 15mg/mL RII-175 was diluted 1:10 in DMEM with 10%
FCS. 25uL of the diluted RII-175 was added to the RBCs (1uM RII final concentration)
and the mixture incubated on ice for one hour. The RBCs were then washed three times
with DMEM with 10% FCS. FITC conjugated anti-his antibody from Invitrogen was
diluted 1:500 in DMEM with 10% FCS. 100uL of the diluted antibody was added to the
washed RBC and incubated on ice for one hour. The RBCs were then washed three
times. The RBCs were then resuspended in 2mL DMEM with 10% FCS. The RBCs
were then analyzed using a BD FACScanto machine. All conditions were conducted in
triplicate.
4.2.2: Treatment of RBCs. RBCs were incubated with either 2mg/mL Trypsin, 1mg/mL
Chymotrysin, or 20uL of anti-GpA antibody from Santa Cruz Biosystems overnight at
4oC. The treated RBCs were then used in binding assays as described above.
4.2.3: IC50 curves. His tagged 15mg/mL was diluted 1:10 in DMEM with 10% FCS.
Compound (siallylactose (sl), peptide (pep), or siallylactose & peptide(slp)) was added to
25uL of diluted RII-175 to reach the desired concentration in a total of 50uL and the
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mixture incubated at 4oC overnight. The mixture was then added to RBCs prepared as
described above in RII binding and the FACS assay conducted as described above in RII
binding. All concentrations of inhibitor were conducted in triplicate.
4.3: Results
4.3.1: Receptor Specificity of RII-175
To test receptor specificity, I examined the effects of established enzyme
treatments on RII-175 binding in the FACS assay described in chapter 3. RII-175-his
was incubated with RBCs that had been treated with chymotrypsin, trypsin, or an
antibody against GpA [fig 20]. RII-175 was able to bind the untreated and chymotrypsin
treated cells but only minimally bound the trypsin and GpA antibody treated cells. The
fluorescence seen in the sample of trypsin treated RBCs with RII-175 is equivalent to that
of RBCs not incubated with RII-175. The reduction in binding seen in the GpA antibody
sample is significant. The binding pattern for trypsin and chymotrypsin is consistent with
previously published data.
4.3.2: IC50 Curves
To look at the influence of the various parts of the receptor, I examined the IC50
of 3’-siallylactose (SL), an unglycosylated peptide of GpA amino acids 27-59 that
correspond to exon 3 (Pep), and 3’-siallylactose and the unglycosylated peptide (SLP).
SL was tested for inhibition because it has been shown that SL on receptors is important
for binding in rosetting assays and can inhibit binding slightly on its own. The
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unglycosylated peptide was tested for inhibition to determine the importance of the
peptide backbone for binding of receptor by RII-175. RII-175-his was incubated
overnight at 4oC in the presence of varying concentrations of SL, Pep, or SLP in the
absence of RBCs. The samples were then incubated with RBCs and afterward incubated
with anti-his antibody. The compounds SL, Pep, or SLP inhibited binding in the FACS
assay to varying degrees [fig 21]. The SL alone was able to inhibit RII-175 binding at an
IC50 concentration of 13mM. The Pep alone was unable to inhibit the RII-175 binding
as shown by the IC50 concentration of >100mM. The SLP was slightly worse inhibitor
of RII-175 binding with an IC50 concentration of 40mM.
4.4: Discussion
The RII-175 expressed and purified is functional and binds to GpA. The receptor
specificity is supported by the RII-175 binding to chymotrypsin treated RBCs but not to
trypsin treated cells. The receptor specificity is further supported by the reduction in
binding upon RBC treatment with anti-GpA antibody, which blocks RII-175 binding by
specifically targeting the receptor. It is also interesting that the trypsin cleaves at amino
acids 31 and 39, which are in exon 3. This implies that this region may be important for
RII-175 binding. The IC50 for SL was in the low milimolar range and implies that SL,
while important for binding, is not the only portion of the receptor responsible for
interaction with RII-175. The peptide incontrast did not inhibit binding under similar
conditions. This may be due to the peptide lacking glycosylation, which is known to be
important for binding. Further studies would be to identify the minimal binding domain
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of GpA by FACS inhibition assays using GpA truncations and GpA glycosylation
mutants.
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Figure 20: Erythrocyte binding by RII-175 in FACS. Trypsin
treatment of erythrocytes or addition of an anti-glycophorin A
antibody prevent binding of recombinant RII-175 while
chymotrypsin treatment has no effect.
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b)

a)

c)
Figure 21: IC50 curves a) 3’-siallylactose (SL), b) peptide corresponding to truncation
4A (peptide), c) SL + peptide
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Chapter 5: Protein/Protein Interaction Studies and Dimerization
5.1: Introduction
There are many methods that can be used to characterize protein/protein
interactions. These methods include pulldowns, analytical ultracentrifugation (AUC),
and multi-angle-light-scattering (MALS). All three methods will be discussed in this
chapter. In a pulldown, protein/protein interactions are characterized using a tagged
protein of interest as “bait” for other proteins. The tagged protein can be immobilized on
agarose beads that are coupled to either a binding partner or antibody for the tag. This
allows for controlled experiments with a known amount of the tagged protein of interest.
The immobilized protein can then be used to pull other proteins that can bind the “bait”
out of solution. The tagged protein of interest and its binding partners can then be
determined through electrophoresis. The advantage of this method is that it can help to
determine previously unknown binding partners for the “bait” protein and verify known
binding partners. The drawback of this method is that it cannot characterize the kinetics
or stoichiometry of binding.
AUC has several advantages over pulldowns, one of which is that it can analyze
molecular weights of complexes in solution along with affinity constants for complexes.
In AUC, the samples can range from hundreds of Daltons to many millions of Daltons
and can be used to obtain the average molecular weight of components in solution [20,
21]. In a sedimentation equilibrium AUC experiment, samples are centrifuged at a set
speed and the sample allowed to reach equilibrium where the amount of diffusion is equal
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to that of the sedimentation. At equilibrium, larger molecules will sediment towards the
bottom of the sample channel and smaller molecules will remain towards the top of the
channel. Multiple speeds and concentrations can be analyzed together because the
molecular weight at any point for a system at equilibrium is dependent on total
concentration but is independent of rotor speed or radial position of the sample in the
rotor [20, 21].
The molecular weight of the sample can be analyzed using linear regression with
set models of association [20, 21]. The first model used is usually a 1-component ideal
model, which can give the average molecular weight of the molecules in solution. It is
best used with a known molecular weight of the possible species in solution. If the
average molecular weight is not that of the monomer and the monomer weight cannot be
fit, it indicates that a monomer-n-mer equilibrium may be occurring. If that is the case, a
monomer-n-mer model can then be used to obtain the equilibrium constants for the
molecule. The n-mer can be varied to achieve the best fit and may be suggested by the
average molecular weight from the 1-component ideal model [20, 21]. It is the advantage
of being able to determine molecular weight of molecules in solution and the association
constants for complexes that make this method ideal for the analysis of RII-175
dimerization and interactions between RII-175 and components of its receptor GpA.
MALS can also determine the molecular weight of proteins and protein
complexes in solution [22, 23]. A typical MALS consists of a size-exclusion
chromatography column coupled with two to three detectors. The detectors commonly
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used are a light-scattering detector and a refractive index detector. An UV absorbance
detector can also be used in conjunction with the other detectors. The data from the
detectors can be used to determine the size of the protein or complex as it is eluted from
the size-exclusion column. The molecular weight can be determined when both the light
scattering and refractive index are determined because the amount a protein scatters light
is directly proportional to its size. While it is relatively straight forward to determine the
molecular weight of a single protein, calculating the stoichiometry of a complex is
slightly more complex. To determine a stoichiometry for a complex from MALS data,
one must assume a given stoichiometry and verify if that stiochiometry fits the data given
[22, 23]. There are a few drawbacks to using MALS to characterize protein-protein
interactions and they include that it requires a higher affinity interaction and equilibrium
constants cannot be determined.
In this chapter, I will describe experiments designed to characterize the
dimerization of RII-175. These experiments include a pulldown with tagged and
untagged RII-175, AUC sedimentation equilibrium experiment with and without GpA,
and MALS.
5.2: Materials and Methods
5.2.1: RII-175 self association as shown through Pulldowns. 1uL of 1:10 diluted
untagged RII-175 and 1:10 diluted his tagged RII-175 were incubated together on Nickelagarose beads with His-tag buffer A for 30 min on ice. The beads were then washed 3
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times. The beads were then resuspended in 10uL of SDS-PAGE dye and the samples run
on a 8% SDS-PAGE gel.
5.2.2: AUC.
5.2.2.1: Optimization of Solution Conditions for RII-175 self association: RII-175
was buffer exchanged three times using a spin concentrator with either HEPES pH 7.4
50mM NaCl, HEPES pH 7.4 100mM NaCl, or HEPES pH 7.4 150mM NaCl. The buffer
exchanged RII-175 was then diluted to an absorbance at 280nm of 0.8, 0.6, or 0.4. The
samples were then run as an equilibrium experiment on a Beckman-Coulter ProteomeLab
XL-A analytical ultra-centrifuge. Ultrascan was used to analyze the data produced by the
sedimentation experiments.
5.2.2.2.: Determination of the Influence of 3’-siallylactose and GpA Peptide
Backbone on RII-175 Self Association. RII-175 was buffer exchanged three times using
a spin concentrator with either HEPES pH 7.4 150mM NaCl 4.6uM sl, HEPES pH 7.4
150mM NaCl 3uM sl, HEPES pH 7.4 150mM NaCl 1.5uM sl, HEPES pH 7.4 150mM
NaCl 4.6uM pep, HEPES pH 7.4 150mM NaCl 3uM pep, HEPES pH 7.4 150mM NaCl
1.5uM pep, HEPES pH 7.4 150mM NaCl 4.6uM slp, HEPES pH 7.4 150mM NaCl 3uM
slp, or HEPES pH 7.4 150mM NaCl 1.5uM slp. The buffer exchanged RII-175 was then
diluted to an absorbance at 280nm of 0.6, 0.4, or 0.2 (4.6 uM, 3uM, or 1.5uM) according
to the concentration of sl, pep, or slp in the buffer. The samples were then run as an
equilibrium experiment on a Beckman-Coulter ProteomeLab XL-A analytical ultra-
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centrifuge. Ultrascan was used to analyze the data produced by the sedimentation
experiments.
5.2.3: Characterization of RII-175 self association in solution using Multi-angle
Light Scattering. RII-175 at a concentration of either 9uM or 30uM in 300uL was
buffer exchanged three times using a spin concentrator into MALS running buffer
(HEPES pH 7.4 150mM NaCl) and concentrated to 300uL. All 300uL of RII-175
solution was filtered and then injected. The MALS located in the Fremont lab is
composed of an Waters 600S HPLC connected to a Wyatt WTC-030S5 gel filtration
column (5um coated silica, 300-Å pore), a Waters 996 UV/VIS detector, a Wyatt
Optilab-tex refractive index detector, and a Wyatt Dawn-heleos light scattering detector.
Astra software is used in conjunction with the MALS to determine the experimental
molecular weight of the resultant peaks.
5.3: Results
5.3.1: Optimization of RII-175 Pulldown to Characterize Self Association
RII-175 is a dimer in the crystal structure and the dimer model is supported by
mutation studies, but direct interaction between RII-175 monomers has not been
characterized. Therefore, a pulldown protocol was developed for RII-175 dimerization to
show that RII-175 can interact with itself. RII-175-his was used to pulldown RII-175 on
nickel-agarose beads. 5uM RII-175-his and 5uM RII-175 were used in the pulldown. In
the pulldown, RII-175-his was able to bind RII-175 [fig 22]. The control of RII-175 on
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the nickel-agarose beads had a very small amount of non-specific binding, but the amount
seen is not enough to account for that seen in the RII-175/RII-175-his sample.
5.3.2: Optimization of Solution Conditions for RII-175 self association
The optimum conditions for the formation of the dimer in solution have not yet
been defined and to determine the conditions a sedimentation equilibrium experiment
was conducted with RII-175 in HEPES pH 7.4 buffer with either 50mM NaCl, 100mM
NaCl, or 150mM NaCl at speeds of 7.5k, 9k, and 14k. The speeds were chosen according
to the Laue equations were the lowest speed is greater than 1.4 for the equation (M/L)2
and the highest speed is greater than 3 for the equation (H/L)2. M is the ideal speed for
the molecular weight as chosen from a RPM vs. molecular weight vs. approximate
sedimentation coefficient chart originally developed by Chervenka in 1970. Using the
chart and a molecular weight of 70kDa for the monomer of RII-175, the speed for M was
determined to be 9k. L and H, the high and low speeds, were derived from the previous
equations with the chosen M and were determined to be 7.5k and 14k respectively.
Unfortunately, the 14k speed was at meniscus depletion for the dimer and no fit was
obtained for any of the samples at this speed. Fits could also not be obtained for the
highest concentration of RII-175 as based on the variance and residuals and may be due
to overloading the cell.
The samples at 4uM and 2uM RII-175 were first analyzed with a 1-component
ideal model. In the 1-component ideal model, molecular weight can be fixed, as well as,
floated to obtain the average molecular weight of the sample and a fit for each weight
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tested [table 2, fig 23-31]. The monomer and dimer weights, 70kDa and 140kDa
respectively, were fixed for each sample and the fit obtained for each molecular weight.
Neither weight was able to give a reasonable fit as seen by the high variance and the
curved residuals. Each sample was then tested with the molecular weight allowed to
float. When this was done, the variance and residuals became much more reasonable and
the average molecular weight for each sample was obtained. The average molecular
weight for the 50mM NaCl, 100mM NaCl, and 150mM NaCl samples were 98.92kDa,
101.6kDa, and 104.02kDa respectively. The average molecular weight being between
the ideal for the monomer and dimer molecular weight suggests a monomer/dimer
equilibrium.
Based on the results from the 1-component ideal model, a monomer/dimer
equilibrium model was then used to analyze all samples at single concentrations at 7k, 9k,
7k and 9k and at all concentrations at 7k and 9k [table 3 and fig 32-43]. The fits and Kds
were obtained for each concentration of salt [table 3]. The Kd for the 50mM, 100mM,
and 150mM NaCl sample was 13.19uM, 9.75uM, and 7.90uM respectively. The result
that the Kd is in the low micromolar range suggests that the RII-175 is a weak dimer in
solution and that the salt concentration in solution has no influence on dimer formation.
Based on these results, the salt concentration used in subsequent experiments was
150mM NaCl.
5.3.3: Determination of the Influence of 3’-siallylactose and GpA Peptide Backbone
on RII-175 Self Association
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A sedimentation equilibrium experiment was conducted with RII-175 in HEPES
pH 7.4 150mM NaCl buffer with either SL, Pep, or SLP at a ratio to RII-175 of 1:1. The
samples were analyzed with a monomer/dimer equilibrium model and this model was
chosen based on the results from the salt gradient experiment [table 4, fig 44-52]. The
highest concentration of RII-175 was excluded from the analysis of the SL and SLP
samples due to overloading and a small dynamic range of 0.6 to 0.8. The lowest
concentration of RII-175 was excluded from the analysis for the SL and SLP samples
based on the small dynamic range due to underloading. The Kd for the SL and SLP
samples at 7.5k and 9k for the 3uM concentration was 4.19uM and 1.8uM respectively.
The Kd for the Pep sample at all speed and concentrations was 2.20uM. The resulting Kd
for the SL, Pep, and SLP samples is similar but slightly lower to that obtained in the salt
gradient, and this suggests that the presence of 3’-siallylactose and peptide alone and 3’siallylactose and peptide were unable to greatly influence the Kd of dimerization. The
small change in Kd may be due to the SL, PEP, and SLP interacting with the RII-175.
5.3.4: Determination of Oligomerization State in Solution by MALS
To determine if RII-175 is a dimer in solution, MALS was conducted on RII-175
at two concentrations: 9uM and 30uM [fig 53]. 9uM and 30uM are within the range of
the Kd seen in AUC in identical buffer. RII-175 ran at a molecular weight of 73 and 70
kDa respectively. This result is different from that seen in AUC experiments and may be
due to dissociation of the complex on the column as the protein becomes diluted.
5.4: Discussion
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RII-175 is a weak dimer. This is supported by the ability of RII-175-his to bind
RII-175 in the pulldown. This is also supported by the AUC data. In the 1-component
ideal model, the average molecular weight is around 100kDa, which is between that of
the monomer and dimer, 70kDa and 140kDa respectively. The monomer/dimer
equilibrium model also supports the weak dimer with the Kd ranging from 7-13uM for the
salt gradient sedimentation experiment and 1-14uM for the SL, Pep, and SLP
experiments. The dimer is also supported by previous mutation studies. The MALS in
contrast did not show any dimer in solution. The protein may have dissociated on the
column resulting in only a monomer peak. This result may also be explained by the weak
Kd as determined by the AUC.
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Figure 22: RII-175 dimer pull-down on Nickel-agarose beads
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Salt
50mM
50mM
50mM
100mM
100mM
100mM
150mM
150mM
150mM

concentration
4uM, 2uM
4uM, 2uM
4uM, 2uM
4uM, 2uM
4uM, 2uM
4uM, 2uM
4uM, 2uM
4uM, 2uM
4uM, 2uM

MW (kDa)
98.92
70
140
101.6
70
140
104.02
70
140

variance (10^-6)
12.2
49
63.4
12.2
48.3
66.1
19.6
94.5
101

Table 2: 1-Component Ideal Model fits for RII-175 in HEPES pH 7.4 with 50mM,
100mM, or 150mM NaCl

64

50mM
NaCl

4uM

2uM

Figure 23: 1-component ideal model using 70kDa molecular weight (left) 7.5k residuals
(right) 9k residuals

65

50mM
NaCl

4uM

2uM

Figure 24: 1-component ideal model using 140kDa molecular weight (left) 7.5k
residuals (right) 9k residuals
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50mM
NaCl

4uM

2uM

Figure 25: 1-component ideal model using 98.9kDa molecular weight (left) 7.5k
residuals (right) 9k residuals

67

100mM
NaCl

4uM

2uM

Figure 26: 1-component ideal model using 70kDa molecular weight (left) 7.5k residuals
(right) 9k residuals

68

100mM
NaCl

4uM

2uM

Figure 27: 1-component ideal model using 140kDa molecular weight (left) 7.5k residuals
(right) 9k residuals

69

100mM
NaCl

4uM

2uM

Figure 28: 1-component ideal model using 101kDa molecular weight (left) 7.5k residuals
(right) 9k residuals

70

150mM
NaCl

4uM

2uM

Figure 29: 1-component ideal model using 70kDa molecular weight (left) 7.5k residuals
(right) 9k residuals

71

150mM
NaCl

4uM

2uM

Figure 30: 1-component ideal model using 140kDa molecular weight (left) 7.5k residuals
(right) 9k residuals

72

150mM
NaCl

4uM

2uM

Figure 31: 1-component ideal model ussing 104kDa molecular weight (left) 7.5k
residuals (right) 9k residuals
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50mM

100mM

concentration

speed

Kd (uM)

4uM

7.5K

5.59

4uM

9k

4uM

variance (10^-6)

concentration

speed

Kd (uM)

variance (10^-6)

11.50

4uM

7.5K

6.57

10.70

13.16

18.10

4uM

9k

10.02

16.10

7.5k/9k

11.58

15.00

4uM

7.5k/9k

8.44

13.60

2uM

7.5K

12.46

5.79

2uM

7.5K

7.68

7.80

2uM

9k

21.13

8.70

2uM

9k

11.92

10.80

2uM

7.5k/9k

15.83

7.30

2uM

7.5k/9k

9.94

9.50

4uM/2uM

7.5k/9k

13.19

11.50

4uM/2uM

7.5k/9k

9.75

11.40

150mM
concentration

speed

Kd (uM)

variance (10^-6)

4uM

7.5K

3.89

25.30

4uM

9k

7.61

23.90

4uM

7.5k/9k

7.09

27.20

2uM

7.5K

8.59

9.36

2uM

9k

8.56

12.80

2uM

7.5k/9k

7.21

12.10

4uM/2uM

7.5k/9k

7.90

18.60

Table 3: Kd and variance for monomer/dimer equilibrium model for 50mM, 100mM, 150mM
NaCl samples
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50mM

4uM/7k

4uM/9k

NaCl

Figure 32: monomer/dimer model overlays and residuals for 50mM NaCl, 4uM RII-175
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50mM

2uM/7k

2uM/9k

NaCl

Figure 33: monomer/dimer model overlays and residuals for 50mM NaCl, 2uM RII-175
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50mM

4uM/7k, 9k

2uM/7k, 9k

7k

9k

Figure 34: monomer/dimer model overlays and residuals for 50mM NaCl, 7k combined
with 9k
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50mM
NaCl

4uM

2uM

Figure 35: monomer/dimer model (left) 7.5k residuals, (right) 9k residuals for 50mM with
4uM and 2 uM RII-175
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100mM 4uM/7k

4uM/9k

NaCl

figure 36: monomer/dimer model overlays and residuals for 100mM NaCl, 4uM RII175
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100mM 2uM/7k

2uM/9k

NaCl

Figure 37: monomer/dimer model overlays and residuals for 100mM NaCl, 2uM RII175
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100mM

4uM/7k, 9k

2uM/7k, 9k

7k

9k

Figure 38: monomer/dimer model overlays and residuals for 100mM NaCl, 7k combined
with 9k
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100mM
NaCl

4uM

2uM

figure 39: monomer/dimer model (left) 7.5k residuals, (right) 9k residuals for 100mM
NaCl with 4uM and 2uM RII-175
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150mM 4uM/7k

4uM/9k

NaCl

figure 40: monomer/dimer model overlays and residuals for 150mM NaCl, 4uM RII-175
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150mM 2uM/7k

2uM/9k

NaCl

figure 41: monomer/dimer model overlays and residuals for 150mM NaCl, 2uM RII175
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150mM

4uM/7k, 9k

2uM/7k, 9k

7k

9k

Figure 42: monomer/dimer model overlays and residuals for 150mM NaCl, 7k
combined with 9k
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150mM
NaCl

4uM

2uM

Figure 43: monomer/dimer model (left) 7.5k residuals, (right) 9k residuals for 150mM
NaCl and 4uM and 2uM RII-175
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SL
concentration

speed

Kd (uM)

variance (10^-6)

3uM

7.5K

9.52

3.36

3uM

9k

15.82

4.61

3uM

7.5k/9k

4.19

4.24

Pep
concentration

speed

Kd (uM)

variance (10^-6)

4.6uM

7.5K

10.80

8.61

4.6uM

9k

12.50

14.60

4.6uM

7.5k/9k

2.55

12.00

3uM

7.5K

1.54

8.87

3uM

9k

5.41

8.33

3uM

7.5k/9k

0.89

8.30

1.5uM

7.5K

0.89

7.11

1.5uM

9k

1.44

8.11

1.5uM

7.5k/9k

0.79

7.69

4.6uM/3uM/1.5uM

7.5k/9k

1.55

9.50

SLP
concentration

speed

Kd (uM)

variance (10^-6)

3uM

7.5K

3.39

3.80

3uM

9k

8.69

3.80

3uM

7.5k/9k

1.80

4.59

Table 4: monomer/dimer model Kd and variance for SL, pep, and SLP
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SL

3uM/7k

3uM/9k

figure 44: monomer/dimer model overlays and residuals for SL, 3uM RII-175
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SL

3uM/7k, 9k

7k

9k

figure 45: monomer/dimer model overlays and residuals for SL, 7k combined
with 9k

89

PEP

4.6uM/7k

4.6uM/9k

figure 46: monomer/dimer model overlays and residuals for PEP, 4.6uM RII-175
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PEP

3uM/7k

3uM/9k

figure 47: monomer/dimer model overlays and residuals for PEP, 3uM RII-175
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PEP

1.5uM/7k

1.5uM/9k

figure 48: monomer/dimer model overlays and residuals for PEP, 1.5uM RII-175
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PEP 4.6uM/7k, 9k

3uM/7k, 9k

1.5uM/7k, 9k

7k

9k

figure 49: monomer/dimer model overlays and residuals for PEP, 7k combined with 9k
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PEP

4.6uM

3uM

1.5uM

figure 50: monomer/dimer model (left) 7.5k residuals, (right) 9k residuals for PEP, all
speeds and concentrations
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SLP

3uM/7k

3uM/9k

figure 51: monomer/dimer model overlays and residuals for SLP, 3uM RII-175
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SLP

3uM/7k, 9k

figure 52: monomer/dimer model overlays and residuals for SLP, 7k combined with
9k

96

a)

b)
Figure 53: MALS data a) 9uM RII-175

b) 30uM RII-175
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Chapter 6: Monoclonal Antibody Generation
6.1: Introduction
Production of antibodies is an important part of the immune response to
pathogens. It has been previously shown antibodies against EBA-175 offer marginal
protection against P. falciparum [12, 13]. To further understand how antibodies interact
with RII-175 and how they affect receptor binding, mAbs are being generated against
RII-175.
To produce mAbs, mice are injected with antigen and given boosts of the antigen
at prescribed times [fig 54] [24]. The polysera of the mice is then tested for reactivity
against the antigen used. The spleen cells of a positive mouse are then harvested and
fused with a myeloma cells that have a mutation in HGPRT and are grown in media that
contains hypoxanthine and thymidine and aminopterin [fig 54]. Aminopterin blocks
denovo purine and pyrimidine synthesis. The spleen cells are fused with the myeloma
cells and grown in media lacking hypoxanthine. The fused cells will be able to survive
but unfused myeloma cells and B cells will not. The B cells do not survive because they
are primary cells and the myeloma cells that do not fuse will not survive because they do
not have a functional HGRPT enzyme. The fused cells get a functional HGPRT from the
B cells and the ability to grow and divide from the myeloma cells. These hybridoma
cells will then produce antibodies. The hybridoma cells will then be subcloned to
produce mAbs. The mAbs can then be analyzed to for function and epitope [24].
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In this chapter, I describe how mAbs were generated against recombinant RII-175
purified as described in chapter 2. In this chapter I also address the development of an
ELISA protocol for the detection of antibodies reactive to RII-175.
6.2: Materials and Methods
6.2.1: Antibody Generation. Three mice were immunized with RII-175 by Kathy
Sheehan and the Hybridoma Center at Washington University. The mice were given an
additional boost of RII-175 before polysera was collected. Polysera was tested by ELISA
as described below and the most reactive mouse (588) chosen for sacrifice. The spleen
cells of the chosen mouse were fused with myeloma cells by the Hybridoma Center. The
hybridomas were expanded and tested for reactivity against RII-175 by ELISA. The
resulting top 20 highest positive OD450 hybridomas were subcloned by the Hybridoma
Center. The resulting subclones will be analyzed by ELISA and positive subclones will
be further subcloned by the Hybridoma Center and tested by ELISA. The positive
hybridomas will then be tested for function by FACS and epitope determined. A terminal
bleed was also taken from the mouse at the time of sacrifice.
6.2.2: Direct ELISA. RII-175, RII-175-his and DBP were each diluted in Carbonate
buffer pH 9.6 to a concentration of 100ug/100uL. 100uL of diluted protein was added to
each well of three ELISA 96 well plates such that rows A to D were coated with RII-175
(RII-175-his was added to column 1 instead of untagged RII-175) and rows E to H were
coated with DBP. The plates were then left at 4oC overnight to couple the protein to the
plate. The plates were then washed three times with PBS 0.5% tween20. 100uL of 2%
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BSA in PBS 0.5% tween20 was added to each well to block and incubated at room
temperature for one hour. The plates were then washed three times with PBS 0.5%
tween20. Polysera was then diluted in a serial dilution starting at 1:100 and going to
1:1,000,000 in PBS 0.5% tween20. The polysera was then added to columns 2 through 6
and incubated at room temperature for one hour. At the same time a mouse anti-6Xhis
antibody from Invitrogen was diluted to 1:500 and added to column 1 and incubated at
room temperature for one hour. The plates were then washed three times with PBS 0.5%
tween20. 100uL of goat anti-mouse IgG antibody conjugated to HRP diluted 1:5000 was
then added to all wells in columns 1 to 6 and incubated for one hour at room temperature.
The plates were then washed three times with PBS 0.5% tween20. 100uL of TMB
substrate was added to all wells in columns 1 to 6 and immediately quenched with 100uL
2M Sulfuric acid. Pictures of each plate were then taken and then the plates were read at
a wavelength of 450nm.
6.2.3: Inhibition of RII-175. His tagged 15mg/mL was diluted 1:10 in DMEM with
10% FCS. Polysera from mouse 588 immunized with RII-175 and mouse 592
immunized with DBP were added to 25uL of diluted RII-175 to reach the desired
concentration in a total of 50uL and the mixture incubated at 4oC overnight. The mixture
was then added to RBCs prepared as described in RII binding in chapter 4 and the FACS
assay conducted as described in chapter 4. All concentrations of polysera were conducted
in triplicate.
6.3: Results
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6.3.1: Reactivity of Mouse Polysera
Three mice were immunized with RII-175 to produce antibodies against RII-175.
To determine if the mice produced antibodies against RII-175, polysera was obtained
from each mouse. The polysera from the three mice (588, 589, 590) was diluted in a
serial dilution (titer) and tested in triplicate for reactivity against RII-175 by ELISA [fig
55]. Mouse 588 had positive titers up to 1:100,000. Mice 589 and 590 had positive titers
up to 1:10,000. Mouse 588 was chosen to be sacrificed to produce hybridomas because it
had the highest titer of antibodies reactive to RII-175.
6.3.2: Reactivity of Fusions
To produce immortal cell lines that can produce antibodies against RII-175,
mouse 588’s spleen cells were fused with myeloma cells to produce hybridomas
(fusions). The fusions were tested twice for reactivity against RII-175 using ELISAs.
The fusions were tested at two time points because a false positive can be seen at the first
time point due to B-cells that have not fused with the myeloma cells and continue to
produce antibodies until they die. The second time point will not have production of
antibodies from unfused B-cells. The ELISAs resulted in 138 wells that had a positive
reading of >0.2 at 450nm [fig 56-59]. The fusions with the 20 highest readings were
chosen to be subcloned. The fusions with the next 20 highest readings were chosen to be
expanded and individually frozen for future studies [fig 60]. The other fusions were
pooled and frozen for future studies.
6.3.3: Reactivity of First Round of Subcloned Cell lines
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To ensure that the cell lines are clonal, the top 20 highest OD450 for the fusions
were subcloned using a serial dilution in 96 well plates were row A was seeded with
100cells/well, row B was seeded with 10cells/well, and rows C to H were seeded with
1cell/well. The subclones were tested for reactivity against RII-175 using ELISAs as
described above. The three highest OD450s in each cell line for wells with a dilution of 1
cell/well were determined and the highest of these three wells was chosen to further
subclone, while the other wells were expanded and frozen [table 5]. If a cell line did not
have any positive readings in rows C to H, the top three highest OD450s in row B or row
A were chosen and the highest of these three wells was chosen to further subclone, while
the other wells were expanded and frozen [table 5]. These cell lines will need to undergo
an extra round of subcloning to insure the culture is clonal. Three cell lines (2F2, 2F7,
and 2D7) failed to produce positive subclones at any dilution on multiple plates. The
other cell lines all produced positive subclones.
6.3.4: Inhibition of RII-175 RBC binding by Mouse Polysera
It is currently unknown how the antibodies produced by the mouse will interact
with RII-175. In order to begin to understand this, the mouse polysera was tested for its
ability to inhibit RII-175 binding to RBCs. Mouse polysera was incubated overnight with
RII-175. The mixture was then incubated with RBCs. FACS was then done on the RBC
mixtures. All dilutions of polysera were able to inhibit binding of RII-175 to RBCs [fig
61]. The dilution 1:5 had the greatest inhibition of binding followed by the 1:10 dilution.
The 1:50 dilution showed minimal inhibition of binding. The inhibition suggests that at
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least some of the antibodies in the polysera can inhibit binding of RBCs by RII-175.
Any mouse RBCs that may be present in the polysera should not inhibit binding because
the terminal sialic acids on the O-glycans on GpA are acetylated. This modification has
been shown to block binding by RII-175 to the mouse RBCs. Although the mouse RBCs
should not inhibit binding, the result could also be explained by the presence of proteases
or other components found in the polysera. The purified monoclonal antibodies will
eventually provide better evidence for inhibition of RII-175 binding to RBCs.
6.4: Discussion
Mice have been immunized with RII-175 and the titers of the mice tested. All
three mice had positive titers to 1:10,000 and mouse 588 was chosen to be sacrificed for
formation of hybridomas. The hybridomas were created and 20 chosen to be subcloned
based on ELISA results. Of the subcloned cell lines, 3 failed to produce positive
subclones in the first round while the other 17 produced positive subclones. The
subclones still need to undergo a second round of subcloning before the antibodies can be
deemed monoclonal. The polysera was also tested for inhibition of RII-175 binding to
RBCs. The polysera was able to inhibit binding, but further characterization remains.
The antibodies produced by the hybridomas will also be characterized individually for
binding of RII-175, neutralization of binding in FACS assys, and epitope.
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a)
b)

figure 54: a) diagram of the production of mAbs, b) diagram of requirements for fusion
media [24]
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figure 55: a) graph of titers for mouse 588, b) ELISA plate and readings for mouse 588,
c) ELISA plate and readings for mouse 589, d) ELISA plate and readings for mouse 590
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figure 56: ELISA results for plate 1 of fusions
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figure 57: ELISA results for plate 2 of fusions
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figure 58: ELISA results for plate 3 of fusions
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figure 59: ELISA results for plate 4 of fusions
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figure 60: OD450 readings for the highest 20 positive fusions chosen for subcloning, the
label on the x-axis refers to the plate number, row value, and well number
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table 5: ELISA Results for Subcloned Cell Lines
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figure 61: Inhibition of RII-175 binding to RBCs by Mouse 588 polysera in FACS
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Chapter 7: Summary of Results and Discussion of Future Directions
Approximately 2 million individuals a year die from malaria each year and an
additional 200 million develop clinical illness characterized by the invasion and lysis of
RBCs by Plasmodium parasites in the erythrocyte life stage [1, 2]. Plasmodium
falciparum is the deadliest of the species of parasite that infect humans, and a large
variety of proteins and cellular processes have been identified as potential targets for
vaccines and drugs including EBA-175 [1, 2, 5].
EBA-175 is part of the EBL family and the sialic acid dependent pathway and is
important for binding erythrocytes [1, 5]. The receptor for EBA-175 is GpA, a
transmembrane glycoprotein on the surface of RBCs [6, 15, 16]. GpA contains 15 Olinked glycans and 1 N-linked glycan and the terminal α2-3 linked sialic acid from Olinked glycans is essential for EBA-175 binding [15, 16].
The structure of RII of EBA-175 reveals a dimer where each monomer is
composed of one F1 and one F2 domain [5]. In the dimer, the F1 of one monomer
interacts with the F2 of the other monomer in a handshake configuration creating two
highly basic channels through the center of the dimer. Six glycan binding sites can also
be found in the dimer with 4 sites inside the channels and the other 2 on the receptor
facing surface. Mutations in the dimer interface and glycan binding sites showed a loss
of RBC binding in rosetting assays indicating possible mechanisms of receptor/ligand
interactions [5].
7.1: Components of the Receptor/Ligand System
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The components of the receptor/ligand system consist of the RBC receptor GpA
and the malaria ligand EBA-175. Previously both EBA-175 and GpA had been produced
using Pichia pastoris and CHO cells respectively [5, 14]. The previous protocol
developed for the production of EBA-175 was labor and time intensive and required the
use of glycosylation mutants [5]. Also, the protocol for production of GpA only
produced transmembrane anchored GpA in small quantities [14]. These protocols were
not easily adaptable for producing the large quantities needed for biophysical
experiments. As a result, a protocol to purify RII-175 and F2-175 from E. coli was
developed and optimized for ease of production of large quantities of protein. The final
yield for this protocol is approximately 1 to 5 mg/L refolding buffer. A protocol for the
production of full length GpA and GpA truncations using HEK293 cells was also
developed and optimized. The final yield for this protocol is approximately 13mg/L
harvested media. The production of purified RII-175 and GpA allows for further
investigation into the interactions between RII-175 with itself and its receptor.
7.2: Characterization of RII-175/GpA Interactions
To show that RII-175 and GpA (full length and truncations) are functional, a
pulldown protocol was developed. In the pulldown, RII-175 binds both full length Gpa
and truncation 4; and it is likely that this region of GpA, amino acids 30 to 50, is the
minimal binding site for RII-175. RII-175 also binds truncation 2, which contains seven
glycosylations and an additional three residues that could potentially be glycosylated,
weakly and may be due to the large number of glycosylations. The importance of the
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glycosylations on GpA is also seen in the pulldown with the anion exchange purified
GpA. In this pulldown, RII-175 binds only the high molecular weight peaks which may
correspond to a higher level of glycosylation.
A second functional assay was developed to test the influence of inhibitors on
RII-175 binding RBCs and to characterize its interactions with GpA. In the FACS assay,
RII-175 binds GpA on human RBCs and is detected through a fluorescently conjugated
antibody against the 6X-his tag on the RII-175. FITC-RII-175 was also developed to
decreases the amount of time required for the FACS assay and can be used to test
inhibitors but not antibodies against RII-175 because the label could interfere with the
ability of antibodies to bind their epitope. This assay was used to characterize the
receptor specificity of the recombinant RII-175 and the inhibition of RII-175 binding by
portions of the receptor.
The RII-175 bound GpA on the RBCs and this is supported by the RII-175
binding to chymotrypsin treated RBCs but not to trypsin treated cells. The receptor
specificity is further supported by the reduction in binding upon RBC treatment with antiGpA antibody, which blocks RII-175 binding by specifically targeting the receptor. The
receptor is composed of both an amino-acid backbone and a large number of
glycosylations that terminate in an α2-3 linked sialic acid. The ability of 3’-siallylactose
and peptide backbone were tested for their ability to inhibit RII-175 binding. The IC50
for SL was in the low milimolar range and implies that SL, while important for binding,
is not the only portion of the receptor responsible for interaction with RII-175. Peptide
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backbone and peptide backbone with SL was not able to inhibit better than SL alone.
Further studies would be to verify the minimal binding domain of GpA by FACS
inhibition assays using GpA truncations and GpA glycosylation mutants.
7.3: Dimerization of RII-175
RII-175 is a weak dimer. Previously, mutation studies were used to support the
dimer model[5]. This is now also supported by data from pulldowns and AUC
experiments but not by MALS. RII-175-his is able to bind RII-175 in the pulldown
indicating that the recombinant protein can interact with itself likely as a dimer.
Dimerization is also supported by the AUC data. In the 1-component ideal model, the
average molecular weight is around 100kDa, which is between that of the monomer and
dimer, 70kDa and 140kDa respectively. The monomer/dimer equilibrium model also
supports the dimer with the Kd ranging from 7-13uM for the salt gradient sedimentation
experiment and 1-14uM for the SL, Pep, and SLP experiments. This experiment has yet
to be done in the presence of GpA. In the presence of GpA, the RII-175 should transition
to being mostly dimeric in the sample based on the proposed dimer model of binding.
The MALS in contrast did not show any dimer in solution. This result may also be
explained by the weak Kd and on-column dissociation.
7.4: Production of mAb against RII-175
Previous studies have shown that antibodies against RII-175 are present in patient
sera[12, 13]. To better understand how antibodies against RII-175 interact with RII-175,
monoclonal antibodies against RII-175 are being produced. To date, three mice have
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been immunized with RII-175 and the titers of the mice tested. All three mice had
positive titers to 1:10,000 and mouse 588 was chosen to be sacrificed for formation of
hybridomas. The hybridomas were created and 20 chosen to be subcloned based on
ELISA results. Of the subcloned cell lines, 3 failed to produce positive subclones in the
first round while the other 17 produced positive subclones. The subclones still need to
undergo a second round of subcloning before the antibodies can be deemed monoclonal.
While the polysera inhibited RII-175 binding to RBCs, the antibodies produced by the
hybridomas have yet to be characterized individually for binding of RII-175,
neutralization of binding in FACS assys, and epitope.
7.5: Future Directions
While dimerization has been shown to occur with RII-175 samples in the absence
of receptor, the significance of dimerization in receptor binding has yet to be determined.
This could be determined through sedimentation equilibrium experiments with RII-175 in
the presence of receptor, co-crystallization of RII-175 with GpA, and the mechanism of
inhibition of RII-175 binding by antibodies. These experiments can also be used to
verify the minimal binding domain of GpA. Characterization of how RII-175 interacts
with GpA can ultimately be used to develop vaccines against malaria.
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